ELAN Elancodata gap · 86% coverage
Health Care · Pharmaceuticals · close $23.55 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Elanco (ELAN) has a ThetaGrade House Rating of 38/100 (grade D), ranking #140 of 150 in Health Care. Its strongest pillars are valuation (73) and profitability (45); its weakest is balance sheet (23). Data gap: 3 factors without usable data, so 86% of the method weight is covered. TTM revenue growth is 12.0% and operating margin 1.6%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, P/E (inverted). Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 86% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 29| Revenue growth YoY (TTM) (13.3%) | 12.0% | 57 |
| EPS growth YoY (TTM) (13.3%) | -146.0% | 6 |
| Revenue acceleration (6.7%) | -4.7% | 17 |
Profitability
weight 18.5% (→20.0%) · 45| Operating margin (10.7%) | 1.6% | 27 |
| 4Q gross-margin change (9.3%) | 0.6% | 65 |
Balance sheet
weight 18.5% (→20.0%) · 23| Net debt / EBITDA (10.7%) | 4.17× | 13 |
| Current ratio (5.3%) | 2.05 | 43 |
| Interest coverage (4.0%) | 0.37× | 22 |
Cash flow
weight 12.33% (→13.3%) · 40| FCF margin (6.7%) | 6.0% | 34 |
| FCF yield (6.7%) | 2.4% | 46 |
Valuation
weight 12.33% (→13.3%) · 73| P/E (inverted) (0.0%)data gap | — | — |
| EV/Sales (inverted) (13.3%) | 2.98× | 73 |
Technicals (EOD)
| RSI(14) | 58.4 |
| EMA 9 / 21 | 22.89 / 22.82 · crossed up 1d ago |
| 200-day SMA | 23.82 |
| Volume vs 20d avg | 0.95× |
| 20-day return | 3.6% |
Exit-rule monitor
- EXITRating break: House Rating below 60
- EXITBalance-sheet stress: net debt/EBITDA above 4×
- WATCHTrend: close below 200-day average
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: GrossProfit · Operating income: Pretax income + interest expense (EBIT proxy) · Interest expense: InterestExpenseOperating · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close.
Get rating changes like ELAN's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is ELAN's House Rating?
- ELAN scores 38 out of 100 (grade D) as of 2026-10-16, ranking #140 of 150 Health Care stocks we cover.
- What do analysts say about ELAN?
- We do not have enough analyst-sentiment data to score this stock.
- When does ELAN report earnings next?
- ELAN's next earnings report is estimated for about 2026-11-04 (window 2026-11-01 to 2026-11-07), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is ELAN a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology